《BioWorld,7月9日,Mylan gets remdesivir approval for COVID-19 in India》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-07-15
  • Mylan gets remdesivir approval for COVID-19 in India

    July 9, 2020

    By David Ho

    HONG KONG – The Drug Controller General of India (DCGI) has approved Mylan NV’s remdesivir 100-mg vial for restricted emergency use in COVID-19 cases.

    The drug received an accelerated approval for the treatment of COVID-19 in adults and children hospitalized with severe presentations of the disease. It will be released in India under the brand name Desrem, and be available to patients at a price of INR4,800 (US$64.34) this month.

    Mylan claims its price for the India market is more than 80% less than the price at which the branded version of remdesivir will be available to governments in the developed world. Its remdesivir will be manufactured in India at its injectables facilities there.

    Mylan is one of the six Indian pharma companies that have received nonexclusive licenses from Gilead Sciences Inc. to manufacture and distribute generic remdesivir in 127 low- and middle-income countries. The approval from the DCGI in India represents the first for Mylan in those 127 markets.

  • 原文来源:https://www.bioworld.com/articles/436341-mylan-gets-remdesivir-approval-for-covid-19-in-india
相关报告
  • 《12月9日_不同的炎症特征可区分COVID-19与流感》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-12-23
    • Science Advances期刊于12月9日发表了美国华盛顿大学医学院等的文章“Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm”,文章称不同的炎症特征将COVID-19与流感区分开来,但细胞因子风暴的作用有限。 文章称,研究人员开展了COVID-19和流感患者免疫应答的研究。与流感患者相比,COVID-19患者在选定的单核细胞群上表现出大致相同的淋巴细胞计数,较少的单核细胞和较低的II型表面人类白细胞抗原(HLA)表达。此外,中间单核细胞的HLA-DR降低预示了严重的COVID-19疾病。与普遍的假设相反,很少(168例中有7例)COVID-19患者表现出细胞因子特征,表明存在细胞因子风暴综合征。在对年龄和样本时间点等多个因素进行控制后,COVID-19患者表现出的细胞因子水平低于流感患者。IL-6、G-CSF、IL-1RA和MCP1的上调预测了COVID-19患者的死亡,但在统计学上不高于流感患者。单细胞转录谱揭示了COVID-19患者中干扰素信号传导的显著抑制。从外围免疫谱的各个方面考虑,与流感患者相比,COVID-19患者出现炎症的可能性较小。 来源:https://advances.sciencemag.org/content/6/50/eabe3024
  • 《NEJM,5月22日,Remdesivir for the Treatment of Covid-19 — Preliminary Report》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-05-23
    • Remdesivir for the Treatment of Covid-19 — Preliminary Report List of authors. John H. Beigel, M.D., Kay M. Tomashek, M.D., M.P.H., Lori E. Dodd, Ph.D., Aneesh K. Mehta, M.D., Barry S. Zingman, M.D., Andre C. Kalil, M.D., M.P.H., Elizabeth Hohmann, M.D., Helen Y. Chu, M.D., M.P.H., Annie Luetkemeyer, M.D., Susan Kline, M.D., M.P.H., Diego Lopez de Castilla, M.D., M.P.H., Robert W. Finberg, M.D., et al., for the ACTT-1 Study Group Members* Article Abstract BACKGROUND Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), none have yet been shown to be efficacious. METHODS We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults hospitalized with Covid-19 with evidence of lower respiratory tract involvement. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only.